NANOBIOTIX将于2024年6月18日举办虚拟KOL活动，讨论NBTXR3与免疫疗法联合治疗头颈部癌症及其后的潜力-动脉网

NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024

BioSpace 等信源发布 2024-06-12 11:58



可切换为仅中文







PARIS and CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that it will host a virtual KOL (Key Opinion Leader) event Tuesday June 18, 2024 at 9:00-10:30AM EDT / 3:00-4:30PM CEST..

巴黎和剑桥，马萨诸塞州，2024年6月12日（环球通讯社）——NANOBIOTIX（泛欧交易所：NANO–纳斯达克：NBTX–the“公司”），一家临床晚期生物技术公司，开创了基于物理的方法来扩大癌症患者的治疗可能性，今天宣布将于2024年6月18日星期二上午9:00-10:30/下午3:00-4:30在CEST举办一场虚拟KOL（关键意见领袖）活动。。

The event will feature several KOLs, including Study 1100 Coordinating Investigators Dr Colette Shen, MD, PhD and Dr Ari Rosenberg, MD, and Dr Jeffrey Bockman, PhD, will moderate the event. The KOLs will join Dr Sebastien Paris, PhD, from the Company to provide an in-depth review of NBTXR3 and the data recently presented at the 2024 Annual Meeting of American Society for Clinical Oncology (ASCO), showing disease control and tumor response in patients treated with radiotherapy-activated NBTXR3 followed by anti-PD-1 for 2nd line or further in patients with recurrent or metastatic head and neck squamous cell carcinoma naïve or resistant to prior anti-PD-1 therapy..

此次活动将有多个KOL参加，其中包括1100研究协调研究者Colette Shen博士和Ari Rosenberg博士，以及Jeffrey Bockman博士将主持此次活动。KOLs将加入该公司的Sebastien Paris博士，对NBTXR3和最近在2024年美国临床肿瘤学会（ASCO）年会上提交的数据进行深入审查，显示未接受或对先前抗PD-1治疗有抵抗力的复发或转移性头颈部鳞状细胞癌患者接受放射治疗激活的NBTXR3治疗后再接受抗PD-1治疗的患者的疾病控制和肿瘤反应。。

Nanobiotix KOL Call to Discuss the Role of NBTXR3 and Immune Oncology in Advancing Head & Neck Cancer

Nanobiotix KOL呼吁讨论NBTXR3和免疫肿瘤学在头颈部癌症进展中的作用

Topics will include:

主题包括：

NBTXR3’s mechanisms of action

NBTXR3的作用机制

NBTXR3’s local and systemic response

NBTXR3的局部和全身反应

How head and neck cancer patients present and are treated in this setting; unmet needs

头颈部癌症患者如何在这种情况下出现和接受治疗；未被满足的需求

NBTXR3 in recurrent/metastatic head and neck cancer, the 1100 study

NBTXR3在复发/转移性头颈癌中的1100项研究

Participants can click here to register and watch the presentation online; the replay version will be available under the same webcast link shortly after the presentation and will be archived on the Company’s website at www.nanobiotix.com. It is recommended to join 10 minutes prior to the start of the event.

参与者可以单击此处在线注册和观看演示文稿；演示后不久，重播版本将在同一网络广播链接下提供，并将存档在公司网站www.nanobiotix.com上。建议在活动开始前10分钟加入。

Participants are invited to email their questions in advance to investors@nanobiotix.com..

参与者被邀请提前将他们的问题通过电子邮件发送到investors@nanobiotix.com..

About NANOBIOTIX

关于NANOBIOTIX

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life..

Nanobiotix是一家晚期临床生物技术公司，开创了颠覆性的，基于物理的治疗方法，为数百万患者彻底改变了治疗结果；得到致力于改变人类的人们的支持。该公司的理念植根于超越已知范围的概念，以扩大人类生活的可能性。。

Incorporated in 2003, Nanobiotix is headquartered in Paris, France and is listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020. The Company has subsidiaries in Cambridge, Massachusetts (United States) amongst other locations.

Nanobiotix成立于2003年，总部位于法国巴黎，自2012年起在巴黎泛欧交易所上市，自2020年12月起在纽约市纳斯达克全球精选市场上市。该公司在美国马萨诸塞州剑桥市（Cambridge）等地设有子公司。

Nanobiotix is the owner of more than 25 patent families associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

Nanobiotix拥有超过25个专利家族，这些专利家族与三（3）个纳米技术平台相关，应用于1）肿瘤学；2）生物利用度和生物分布；3）中枢神经系统疾病。

For more information about Nanobiotix, visit us at www.nanobiotix.com or follow us on LinkedIn and Twitter.

有关Nanobiotix的更多信息，请访问www.Nanobiotix.com或在LinkedIn和Twitter上关注我们。

Disclaimer

免责声明

This press release contains “forward-looking” statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the use of proceed therefrom, and the period of time through which the Company’s anticipates its financial resources will be adequate to support operations.

本新闻稿包含1995年《私人证券诉讼改革法案》中“安全港”条款所指的“前瞻性”声明，包括但不限于关于使用“收益”的声明，以及公司预计其财务资源足以支持运营的时间段。

Words such as “expects”, “intends”, “can”, “could”, “may”, “might”, “plan”, “potential”, “should” and “will” or the negative of these and similar expressions are intended to identify forward-looking statements. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management.

诸如“期望”、“打算”、“可以”、“可以”、“可以”、“可以”、“可能”、“可能”、“计划”、“潜在”、“应该”和“将会”等词语或这些和类似表达的否定词旨在识别前瞻性陈述。这些前瞻性声明是基于我们管理层当前的期望和假设以及管理层目前可获得的信息。

These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those implied by the forward-looking statements, including risks related to Nanobiotix’s business and financial performance, which include the risk that assumptions underlying the Company’s cash runway projections are not realized.

这些前瞻性报表涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致实际结果与前瞻性报表所暗示的结果存在重大差异，包括与Nanobiotix业务和财务业绩相关的风险，其中包括公司现金流预测基础假设未实现的风险。

Further information on the risk factors that may affect company business and financial performance is included in Nanobiotix’s Annual Report on Form 20-F filed with the SEC on April 24, 2024 under “Item 3.D. Risk Factors”, in Nanobiotix’s 2023 universal registration document filed with the AMF on April 24, 2024, and subsequent filings Nanobiotix makes with the SEC from time to time which are available on the SEC’s website at www.sec.gov.

有关可能影响公司业务和财务业绩的风险因素的更多信息，请参见Nanobiotix于2024年4月24日在“第3.D项风险因素”下提交给SEC的表20-F年度报告、Nanobiotix于2024年4月24日提交给AMF的2023年通用注册文件以及Nanobiotix不时向SEC提交的后续文件，这些文件可在SEC网站www.SEC.gov上查阅。

The forward-looking statements included in this press release speak only as of the date of this press release, and except as required by law, Nanobiotix assumes no obligation to update these forward-looking statements public.

本新闻稿中包含的前瞻性声明仅在本新闻稿发布之日起生效，除法律要求外，Nanobiotix没有义务公开更新这些前瞻性声明。

Contacts

联系人

Nanobiotix

Communications Department

通信部

Brandon Owens

布兰登·欧文斯

VP, Communications

通信副总裁

+1 (617) 852-4835

contact@nanobiotix.com